Paul Handley

585 total citations
15 papers, 482 citations indexed

About

Paul Handley is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Paul Handley has authored 15 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Paul Handley's work include Glycosylation and Glycoproteins Research (5 papers), Proteoglycans and glycosaminoglycans research (4 papers) and Fibroblast Growth Factor Research (3 papers). Paul Handley is often cited by papers focused on Glycosylation and Glycoproteins Research (5 papers), Proteoglycans and glycosaminoglycans research (4 papers) and Fibroblast Growth Factor Research (3 papers). Paul Handley collaborates with scholars based in Australia, United States and Italy. Paul Handley's co-authors include Keith Dredge, Edward Hammond, Ian Bytheway, Vito Ferro, Maree T. Smith, Thomas J. Gonda, Ralf Brandt, Tomislav Karoli, Liwen Lin and Yiping Yang and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and British Journal of Cancer.

In The Last Decade

Paul Handley

15 papers receiving 475 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Handley Australia	8	346	334	135	53	46	15	482
Cai Ping Li Australia	7	323 0.9×	293 0.9×	180 1.3×	26 0.5×	33 0.7×	7	407
Balaji Nagarajan United States	11	225 0.7×	186 0.6×	63 0.5×	42 0.8×	24 0.5×	23	376
Poornima H. Neela United States	7	313 0.9×	150 0.4×	62 0.5×	37 0.7×	40 0.9×	7	419
Pierre‐Alexandre Driguez France	12	377 1.1×	348 1.0×	303 2.2×	18 0.3×	50 1.1×	21	691
Tim Wong Hungary	4	285 0.8×	239 0.7×	57 0.4×	12 0.2×	20 0.4×	4	431
Stephanie Roth United States	10	381 1.1×	195 0.6×	38 0.3×	152 2.9×	21 0.5×	11	491
Adam J. Stein United States	11	418 1.2×	45 0.1×	59 0.4×	43 0.8×	73 1.6×	13	603
A A Horner Canada	12	257 0.7×	289 0.9×	57 0.4×	9 0.2×	46 1.0×	19	431
Makoto Kiso Japan	9	323 0.9×	88 0.3×	188 1.4×	31 0.6×	18 0.4×	10	408
William Guerrant United States	12	540 1.6×	107 0.3×	227 1.7×	156 2.9×	19 0.4×	12	718

Countries citing papers authored by Paul Handley

Since Specialization

Citations

This map shows the geographic impact of Paul Handley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Handley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Handley more than expected).

Fields of papers citing papers by Paul Handley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Handley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Handley. The network helps show where Paul Handley may publish in the future.

Co-authorship network of co-authors of Paul Handley

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Handley. A scholar is included among the top collaborators of Paul Handley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Handley. Paul Handley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Hammond, Edward, Nicole M. Haynes, Carleen Cullinane, et al.. (2018). Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. Journal for ImmunoTherapy of Cancer. 6(1). 54–54. 35 indexed citations

Dredge, Keith, Todd V. Brennan, Edward Hammond, et al.. (2018). A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. British Journal of Cancer. 118(8). 1035–1041. 73 indexed citations

Elli, Stefano, Paul Handley, Anthony R. Carroll, et al.. (2018). Structural and conformational studies of the heparan sulfate mimetic PI-88. Glycobiology. 28(10). 731–740. 15 indexed citations

Handley, Paul, Anthony R. Carroll, & Vito Ferro. (2017). New structural insights into the oligosaccharide phosphate fraction of Pichia ( Hansenula ) holstii NRRL Y2448 phosphomannan. Carbohydrate Research. 446-447. 68–75. 14 indexed citations

Hammond, Edward, Paul Handley, Keith Dredge, & Ian Bytheway. (2013). Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues. FEBS Open Bio. 3(1). 346–351. 51 indexed citations

Ferro, Vito, Ligong Liu, Ken D. Johnstone, et al.. (2012). Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis. Journal of Medicinal Chemistry. 55(8). 3804–3813. 108 indexed citations

Dredge, Keith, Edward Hammond, Paul Handley, et al.. (2011). PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. British Journal of Cancer. 104(4). 635–642. 147 indexed citations

Dredge, Keith, Edward Hammond, Paul Handley, et al.. (2011). Abstract 1461: The heparan sulfate mimetic PG545 potently inhibits spontaneous lung metastasis and significantly enhances overall survival in the 4T1 breast carcinoma model. Cancer Research. 71(8_Supplement). 1461–1461. 1 indexed citations

Bytheway, Ian, Edward Hammond, Paul Handley, & Keith Dredge. (2009). Abstract A18: The dual angiogenesis/heparanase inhibitor PG545, but not the tyrosine kinase inhibitor sorafenib, inhibits spontaneous metastasis in models of breast and lung cancer. Molecular Cancer Therapeutics. 8(12_Supplement). A18–A18. 1 indexed citations

10.

Hammond, Edward, Ian Bytheway, Paul Handley, et al.. (2009). Abstract A17: The dual angiogenesis/heparanase inhibitor PG545 inhibits solid tumor progression in models of breast, prostate and liver cancer: A comparative assessment of once versus twice weekly administration schedules. Molecular Cancer Therapeutics. 8(12_Supplement). A17–A17. 1 indexed citations

11.

Handley, Paul, et al.. (2003). Sodium Perborate—A Convenient Baeyer–Villiger Oxidation Reagent in the Synthesis of the Corey Aldehyde. Advanced Synthesis & Catalysis. 345(3). 325–327. 6 indexed citations

12.

Handley, Paul, et al.. (2002). 9,10-Dihydroxy-1,8-cineole (1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane-10,11-diol). Australian Journal of Chemistry. 54(12). 769–776. 7 indexed citations

13.

Handley, Paul, et al.. (2000). 2-Hydroxy-4-oxohenicosan-1-yl Acetate. Its Presence in Avocado and its Simple Chemistry. Australian Journal of Chemistry. 53(3). 191–194. 4 indexed citations

14.

Kadirvelraj, Renuka, et al.. (1999). The Stereochemical Structures of the Furanosesquiterpenoidal β -Hydroxy Ketones from the Myoporaceae. Australian Journal of Chemistry. 52(8). 727–732. 5 indexed citations

15.

Handley, Paul, et al.. (1999). Antifungal diene in leaves of various avocado cultivars. Phytochemistry. 50(8). 1329–1331. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact